IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.
8 reports, 1 independent
Updated Mon 00:00
Still developing
Reached 3 outlets in its first 24 hours
- Reports
- 8
- Developments
- 3
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.IGC Pharma is using McGill University and Hamilton Health Sciences as clinical trial sites.1 source
- Both the FDA and the European Medicines Agency are reviewing deucrictibant for approval.Sub-event
Seeking FDA review and EMA support for lead drug candidate.1 source
Keep exploring
The entities involved
- FDA
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- EMA validated marketing authorization and FDA accepted NDA for Pharvaris N.V.'s lead drug.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- The FDA is reviewing drug data and company resubmissions, while also overseeing the functions of the U.S. Department of Health and Human Services.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.